Global Life Science Business Partnering (GLSBP) - July 2023

Highlights of July 2023

 

1. Strides Pharma Science sells manufacturing unit to Biocon subsidiary Syngene for INR 702 crore (~US$94 Million) in cash.

2.      Nirma Group is likely to acquire an 82.84% stake in Glenmark Life Sciences in a deal worth INR 6,664 to INR 7,000 crore (~US$812M – US$853M).

3.      Baring Private Equity Asia (BPEA) EQT to buy 60% stake in India's largest fertility chain Indira IVF.

4.      Cipla promoter family in talks with private equity majors for stake sale.

5.      Warburg in advanced talks to buy medical equipment manufacturer Appasamy.

6.      India resurgence fund in talks to acquire Ind-Swift's API business.

7.      Medanta ties-up with GE HealthCare to launch digital ICU services.

8.      Lipigon signs US$91 Million deal with Leaderna Therapeutics.

9.      AbbVie and Calibr expand strategic collaboration to advance several preclinical and early-stage clinical assets.

10.  Roche partners with Alnylam on RNAi therapeutic zilebesiran.

11.  ImmunoGen inks license and option deal with ImmunoBiochem.

12.  Quince Therapeutics to acquire EryDel.

13.  Astellas inks research deal with PeptiDream.

14.  NorthX has acquired manufacturing unit from Valneva.

Highlights at Aagami:

1.      New Client Win: Global pharma with market ready Denosumab biosimilar to PROLIA® & XGEVA®.

2.      New Client Win: Japan and US based biotech developing highly effective, non-invasive drugs for CNS targeting neurodegenerative diseases.

3.      Aagami CEO Dinesh Jain to attend BIO JAPAN 2023 in Yokohama, Japan (Oct 11-13) to promote client’s market ready Denosumab biosimilar.

4.      Aagami Vice-President to attend Bio-Europe 2023 in Munich, Germany (Nov 6-8).

INFOCUS: Select opportunities available:

For Partnering/Licensing/ Co-development:

  1.    Licensing available for Japan: Market ready Denosumab biosimilar to PROLIA® & XGEVA®.
  2. Licensing/Co-development: Easy to apply world’s First Transdermal Tizanidine Patch for the Management of Spasticity. Impressive Phase 1 results. Ready to initiate Phase 2. 
  3. Licensing for US available: Lidocaine 10% Topical Patch; NDA approval expected in Q4 of 2023. Made using Proprietary drug formulation technology, ILTS® (Ionic Liquid Transdermal Technology). Indication: the treatment of PHN (postherpetic neuralgia). 
  4. Seeking Partnering/JV – Phase 2 Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia.
  5. Seeking licensing/co-development partnerships: A single (monovalent) vaccine for Targeting Salmonella, ETEC / E. coli, Campylobacter, Shigella. Fulfills an unmet need for treating Bacterial Dysentery.

For Acquisition:

  1. Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics and substantial returns. 
  2. Asset Sale -  Oral small molecule oral small molecule modulator of mutant RyR2 for the treatment of CPVT-1/ Heart Arrhythmia.

 Seeking Investment:

  1. Seeking US$15 million for Phase-1 POC: Intranasal Rifampicin (Patented, Orphan Drug Designation) for neurodegenerative diseases (High ROI).
  2. Seeking US$5 million: A single (monovalent) vaccine for Targeting Salmonella, ETEC / E. coli, Campylobacter, Shigella. Fulfills an unmet need for treating Bacterial Dysentery.
  3. $40 Million Series C: On the market, US FDA approved novel portable MRI Guided Treatment, Diagnosis and Screening, for Urology applications. California based client.
  4. Seeking US$200K: Precision fermentation-based technology to produce Natural Soluble Melanin at a cost hundreds of times lower. The current round proceeds will be used to achieve milestone of making a market ready Sunscreen cream using Melanin, under Consumer Health & Wellness category.
  5. Seeking US$5 million: Midwest US based Pharma with Phase 2 stage First-in-Class Non-Opioid Analgesic NCE for Pain Relief.
×
Twitter